<DOC>
	<DOCNO>NCT02965391</DOCNO>
	<brief_summary>Previous study show circulate tumor DNA level reflect total systemic tumor burden . Circulating tumor DNA level decrease complete surgery could increase tumor recurrence . Few study investigate half time circulate tumor DNA lung cancer patient criterion establish use surveillance .</brief_summary>
	<brief_title>Dynamic Changes Circulating Tumor DNA Surgical Lung Cancer Patients</brief_title>
	<detailed_description>For adenocarcinoma patient receive surgery , multiple time plasma collect surgery . A series mutation detect plasma surgery base next generation sequence . The positive mutation trace surgery follow .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Suspected lung cancer surgery No malignant tumor history within past 5 year The pulmonary nodule pure ground glass opacity Patients must give write informed consent Multiple primary lung cancer R1 , R2 resection Histology confirm nonsmall cell lung cancer Unqualified blood sample</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Circulating Tumor DNA</keyword>
	<keyword>Half time</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Surgery</keyword>
	<keyword>Surveillance</keyword>
</DOC>